Outlook on the global diabetic retinopathy market until 2027 –

Dublin, November 14, 2022 (GLOBE NEWSWIRE) – The “Global Diabetic Retinopathy Market Size, Share & Industry Trends Analysis Report by Type, by Treatment Type, by Regional Perspectives and Forecasts, 2021-2027” has been added to by ResearchAndMarkets.com offer.

The global diabetic retinopathy market size is expected to reach $ 7.7 billion by 2027, increasing to an 11.3% CAGR market growth over the forecast period.

Diabetic retinopathy is a critical medical disorder that affects the eyes due to diabetes or inefficient insulin level in the patient’s blood. Impairment of the blood vessels of the photosensitive tissue of the retina is the main cause of diabetic retinopathy. In addition, blurred vision, dark or hollow spots in vision, fluctuating vision, poor color identification and loss of vision are the most typical symptoms of this disorder.

A high blood sugar level causes the small blood capillaries in the retina to block, preventing blood flow. Advanced cases of diabetic retinopathy require laser therapy or surgery. Mild to moderate cases of diabetic retinopathy can be cured with appropriate diabetes management.

Diabetic retinopathy may cause no symptoms or only mild vision abnormalities in the early stages, however it can cause blindness in the early stages. Anyone with type 1 or type 2 diabetes can develop the disease. The longer a person has diabetes, the more likely they are to develop eye complications due to poorly regulated blood sugar levels. Diabetic retinopathy can progress to diabetic retinal detachment, macular edema, and neovascular glaucoma, among other serious eye disorders.

Diabetic retinopathy can also mutate to proliferative diabetic retinopathy, which is a more severe form of the disorder. The affected blood vessels close in this type, leading the retina to develop new, dysfunctional blood vessels. These new blood vessels are fragile and can leak into the clear, jelly-like liquid that fills the center of the patient’s eye.

Non-proliferative diabetic retinopathy, NPDR, is a type of diabetic retinopathy in which symptoms are minimal or absent. New blood vessels are weakened or stop forming in this more common form of diabetic retinopathy. The blood vessel membranes in the retina deteriorate when a patient suffers from NPDR. Small bulges emerge from the walls of smaller vessels, occasionally blood and fluid infiltration into the retina. Even the largest retinal vessels can begin to dilate and their size becomes irregular.

Analysis of the impact of COVID-19

The COVID-19 pandemic has had a severe impact on various economies around the world. Several companies have been significantly devastated due to the outbreak of the COVID-19 infection. Furthermore, the governments of different countries have been forced to impose blockades on their nations.

As a result, the production units of numerous commodities were temporarily closed. Furthermore, these blockages have also caused a major disruption in the supply chain of various goods. Additionally, COVID-19 has led the global healthcare industry to significant bankruptcy due to hospital bed and oxygen shortages. The worldwide COVID-19 outbreak has disrupted healthcare workflows. Various sectors, including numerous subdomains of health care, have been forced to temporarily close their units due to increasing cases of infection.

Market drivers:

Increase in the number of diabetic patients

Diabetes is considered to be the main source of diabetic retinopathy. Therefore, an increase in the number of diabetes patients is expected to directly increase the demand for treatments for diabetic retinopathy. In addition, there is a significant increase in the number of patients with diabetes, due to which the demand for treatment of diabetic retinopathy is continuously increasing.

There is a significant number of people who are concerned about the damage that may be caused to their eyes by the onset of diabetic retinopathy. The diabetic retinopathy market is expected to grow as the prevalence of diabetes increases worldwide. According to the National Center for Biotechnology Information, diabetic retinopathy affected 126 million people in 2010 and is expected to affect more than 191 million people by 2030.

Geriatric population increasing worldwide

Cases of diabetic retinopathy are more common in geriatric people. The prevalence of this disorder appears to be more robust in people over the age of 60.

Furthermore, the number of older people is becoming significant and represents a substantial share of the population in almost all countries, affecting different aspects of society, including financial markets and labor, the demand for goods and services, such as housing, transport, as well as protection. social, together with family structures and intergenerational ties.

According to the United Nations Organization, the world’s elderly population is expected to more than double over the next three decades, reaching 1.5 billion by 2050.

Marketing restriction factor:

Lack of health facilities in developing and underdeveloped economies

People residing in poor countries have less access to health facilities than wealthy people, while poor people have less access to health services within their own countries. In contrast, poor people in low- and middle-income countries, or LMICs, are continuously disadvantaged in various aspects of access, as well as in their determinants.

Furthermore, the health sector in least developed countries is poorly underfunded and the vast majority of these countries are unable to provide basic and basic health services to their citizens. This problem is more prevalent in underdeveloped and developing countries, where government investment in public safety is increasing at the expense of healthcare spending.

Key topics covered:

Chapter 1. Market scope and methodology

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition and scenario
2.2 Key factors affecting the market
2.2.1 Market Driver
2.2.2 Market Restrictions

Chapter 3. Strategies Implemented in the Diabetic Retinopathy Market

Chapter 4. Global Diabetic Retinopathy Market by Type
4.1 Proliferative global market by region
4.2 Global Diabetic Macular Edema (DME) Market by Region

Chapter 5. Global Diabetic Retinopathy Market by Treatment Type
5.1 Global anti-VEGF drug market by region
5.2 Global Steroid Implants Market by Region
5.3 Global Laser Surgery Market by Region
5.4 Global Vitrectomy Market by Region

Chapter 6. Global Diabetic Retinopathy Market by Region

Chapter 7. Company Profiles
7.1 Alimera Sciences, Inc.
7.1.1 Company overview
7.1.2 Financial analysis
7.1.3 Regional analysis
7.1.4 Research and development expenses
7.1.5 Recent strategies and developments:
7.1.5.1 Partnerships, collaborations and agreements:
7.1.5.2 Geographic Expansions:
7.2 F. Hoffmann-La Roche SA
7.2.1 Company overview
7.2.2 Financial analysis
7.2.3 Segmental and regional analysis
7.2.4 Research and development expenses
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, collaborations and agreements:
7.2.5.2 Approvals and tests:
7.3 Bausch Health Companies, Inc.
7.3.1 Company overview
7.3.2 Financial analysis
7.3.3 Segmental and regional analysis
7.3.4 Research and development expenses
7.3.5 Recent strategies and developments:
7.3.5.1 Partnerships, collaborations and agreements:
7.3.5.2 Approvals and tests:
7.4 Bayer AG
7.4.1 Company overview
7.4.2 Financial analysis
7.4.3 Segmental and regional analysis
7.4.4 Research and development expenses
7.4.5 Recent strategies and developments:
7.4.5.1 Approvals and tests:
7.5 Pfizer, Inc.
7.5.1 Company overview
7.5.2 Financial analysis
7.5.3 Regional and segmental analysis
7.5.4 Research and development expenses
7.6 Novartis AG
7.6.1 Company overview
7.6.2 Financial analysis
7.6.3 Segmental and regional analysis
7.6.4 Research and development expenses
7.7 Allergan PLC (AbbVie, Inc.)
7.7.1 Company overview
7.7.2 Financial analysis
7.7.3 Regional analysis
7.7.4 Research and development expenses
7.7.5 Recent strategies and developments:
7.7.5.1 Partnerships, collaborations and agreements:
7.8 Regeneron Pharmaceuticals, Inc.
7.8.1 Company overview
7.8.2 Financial analysis
7.8.3 Research and development expenses
7.8.3.1 Approvals and tests:
7.9 Ampio Pharmaceuticals, Inc.
7.9.1 Company overview
7.10. Kowa Company, Ltd.
7.10.1 Company overview

For more information on this report, please visit https://www.researchandmarkets.com/r/i1yhrh

  • Global Diabetic Retinopathy Market

 
    .

Leave a Reply

%d bloggers like this: